




ISFA



10th International Society for Apheresis Congress

13 – 16 May 2015 | Cancún, Mexico

Program



ISFA 2015 | www.isfacongress.com
Paragon Group - www.paragong.com
18 Avenue Louis-Casai , 1209 Geneva , Switzerland
Email: secretariat@isfacongress.com

TABLE OF CONTENTS

Welcome Message	3
Organization and Invited Speakers	4
General Information	5
Supporting Partners	6
Sponsors	7
Scientific Program	
Wednesday, 13 May 2015	13
Thursday, 14 May 2015	14
Friday, 15 May 2015	18
Saturday, 16 May 2015	22
Abstracts	29
Author Index	67

WELCOME MESSAGE FROM CONGRESS PRESIDENT

Dear Colleagues

On behalf of International Society for Apheresis (ISFA), it is my honor to welcome you to the 10th ISFA Congress in Cancun, Mexico.

Our main objective for the 2015 ISFA Congress is to present the most current technologies and their clinical applications in the field of apheresis. This year, ISFA will collaborate with the Asociacion Mexicana de Medicina Transfusional AC (AMMTAC). With the help of AMMTAC President, Dr. Angel Guerra-Marquez, our aim is to advance the science of transfusion and apheresis medicine.

This year's Congress includes an international group of speakers who will focus on such topics as Atherosclerosis, Immunology, Inflammation, Nephrology, Infectious Disease/Sepsis, Regulatory Issues, Cardiology and Hepatology.

In addition, AMMTAC will present and address issues in the field of transfusion medicine such as blood borne diseases, blood donation, and safety.

We hope that you will be able to attend our scientific congress and take pleasure in the communal activities that we have planned. On the first day, the welcome reception will provide a chance for all of those participating to meet and enjoy an evening of entertainment. There will also be plenty of time to enjoy the incredible natural scenery and culture that Cancun has to offer.

We look forward to welcoming you to Cancun for the Congress in 2015.

Warm regards,



Patrick M. Moriarty

President, ISFA

ORGANIZATION

The Officers and the Board of Trustees 8th Term (2013-2015)

The Officers:

President

P. Moriarty (USA)

President-Elect

W. Szpirt (Denmark)

Immediate Past-President

T. Tani (Japan)

Vice President

A. Torloni (USA)

A. Casian (UK)

M. Yonekawa (Japan)

Secretary Treasurer

Y. Endo (Japan)

Editor-in Chief

T. Akizawa (Japan)

Regional Offices

America: P. Malchesky,

P. Moriarty, A. Torloni

Europe: K. Derfler, J. Klinkmann, V. Witt

Pan-Pacific: H. Tsuda, K. Lin, D. Kong

Invited Speakers

Georg Boehmig

Alina Casian

Yoshihiro Endo

Siami Ghodrat

Bernd Hohenstein

Beate R. Jaeger

Andre Kaplan

Jan Kielstein

Hans-Ulrich Kloer

Rudolf Kunze

Hisashi Makino

Paul Malchesky

Steffen Mitzner

Jody Olson

Christian Peter

Wolfgang Ramlow

Ahmed Sheriff

Wladimir Szpirt

Sotirios Tsimikas

James Underberg

Jörg Vienken

Uwe Wallstab

Grit Waitz

Robert Weinstein

Heinz Wiendl

Anne Winkler

Jeffrey Winters

Volker Witt

GENERAL INFORMATION

Venue

Cancun Center Conventions & Exhibitions
Boulevard Kukulcan KM. 9 1er Piso, Zona Hotelera, 77500
Canun, Mexico
Tel: +52 998 881 0400

Language

The official language of the congress is English

Registration & Hospitality Desk

The Registration desk will operate throughout the meeting in the foyer of the Conventions Center of the hotel at the following hours:

May 13, 2015	15:00-19:00 hrs
May 14, 2015	08:00-17:00 hrs
May 15, 2015	08:00-17:00 hrs
May 16, 2015	08:00-13:00 hrs

E-posters

The E-posters will be presented throughout the congress at the specific E-poster stations.

Get together Reception

A reception will be held on the evening of Wednesday, May 13, 2015, at the Fiesta Americano Coral Hotel, Cancun.

Congress Organizers:



ISFA 2015 | www.isfacongress.com
Paragon Group - www.paragong.com
18 Avenue Louis-Casai , 1209 Geneva , Switzerland
Email: secretariat@isfacongress.com

COLLABORATING ASSOCIATIONS

Belgian Hematological Society
British Blood Transfusion Society
Canadian Apheresis Group
Czech Oncological Society
Danish Society of Nephrology
European Renal Association -
European Dialysis and Transplant Association
FH Foundation
Israel Society of Hematology and Blood Transfusion
National Lipid Association
Sociedad Chilena de Hematología
Sociedad Peruana de Oncología Médica
Sociedad Venezolana de Hematología
Sociedad Venezolana de Oncología
Sociedade Brasileira de Nefrologia
Società Italiana di Nefrologia
The Peruvian Society for Medical Oncology
World Apheresis Association

ENDORSEMENT

European Renal Association- European Dialysis and Transplant Association

MEDIA PARTNERS

Artificial Organs
Haematologica
Therapeutic Apheresis and Dialysis

SPONSORS

Gold Sponsor



Silver Sponsor



Additional Sponsors



SPONSORS

Fresenius



Fresenius Medical Care is the world's largest fully integrated provider of products and services for individuals undergoing dialysis due to chronic kidney failure. Through its network of more than 3,000 dialysis clinics in North America, Europe, Latin America, Asia-Pacific, and Africa, Fresenius Medical Care provides dialysis treatments for 250,000 patients around the globe.

Therapeutic Apheresis, a division of Fresenius Medical Care, is dedicated to provide extracorporeal treatments to patients in whom standard therapy approaches have unfortunately failed. For instance, harmful pathogenic auto-antibodies produced by the patient's own metabolism occur in many clinical settings such as various autoimmune diseases or as responses to transplanted organs. But also genetically impaired high levels of blood cholesterol are a typical indication for Therapeutic Apheresis. As a principle mode of work, Therapeutic Apheresis can be applied to adsorb these pathogens from the patient's blood through the use of selective adsorber columns. This kind of treatment can be performed in repetitive modes in acute or chronic conditions. The advantage of this treatment is the pronounced selective removal of pathogens while the beneficial metabolic particles are retained at the patient's blood.

Immunosorba® and **GLOBAFFIN**® from Fresenius Medical Care are two specific adsorber columns for the treatment of immunoglobuline "G" mediated diseases. They are mainly used for the treatment of autoimmune diseases and antibody mediated transplant rejections (e.g. DCM, Pemphigus, MG, GBS, SLE, AHR).

In patients suffering from severe hypercholesterolaemia, the only effective therapy option to reduce LDL-C and Lp(a) significantly is the lipoprotein apheresis technology with e.g. the apheresis adsorber **DALI**® or double filtration system **MONET**®. With these innovative therapeutic apheresis treatments, FME defines highest standards of care in the treatment of critically sick patients.

Best Theratronics Ltd



Best Theratronics is the world's leading manufacturer of blood and research irradiators. Offering both gamma and x-ray, we have a long history of reliability, support and high-quality products. The Gammacell 1000 and 3000 prevents graft-versus-host disease and are considered the "Gold Standard" in countless clinics worldwide. Our Raycell Mk2 dual x-ray tubes deliver unparalleled dose uniformity across its 2.0 and 3.5 litre canisters. The Gammacell 40 Extractor is the industry's preferential irradiator, making it a welcome addition to research labs. For more information please visit: www.theratronics.ca.

SPONSORS (CONT.)

ISIS Pharmaceuticals



ISIS is exploiting its leadership position in RNA-targeted technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 38 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO®, in the United States and other countries for the treatment of patients with homozygous FH. Isis has numerous drugs in Phase 3 development in severe/rare diseases and cardiovascular diseases. These include ISIS-APOCIII_{Rx}, a drug Isis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with familial chylomicronemia syndrome and partial lipodystrophy; ISIS-TTR_{Rx}, a drug Isis is developing with GSK to treat patients with the polyneuropathy and cardiomyopathy forms of TTR amyloidosis; and ISIS-SMNR_{Rx}, a drug Isis is developing with Biogen Idec to treat infants and children with spinal muscular atrophy, a severe and rare neuromuscular disease. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.

Kaneka Medical Products



Kaneka Corporation is touching the lives of people all over the world with infinite possibilities of chemistry. By further advancing our key of highly innovative technology in producing medical devices and building blocks for active pharmaceutical ingredients (API), macromolecules, fermentation and bioscience, Kaneka is exploring new possibilities beyond the traditional boundaries of chemistry.

Kaneka Pharma Europe N.V. (KPE) is the independent subsidiary for the European market. Lipoproteinapheresis (La(a), LDL), in which Kaneka is one of the pioneers since 1989, is beside the interventional products one of KPE's main business.

SPONSORS (CONT.)

Kaneka Pharma America



Kaneka Pharma America LLC is a wholly owned subsidiary of Kaneka Corporation. Our main offices are located in New York City, NY. We are the exclusive distributor of the Liposorber System in the United States and Canada.

The Liposorber® System has been approved by the FDA for patient use since 1996. Liposorber® is intended for FH patients for whom at least six months of diet and maximum drug therapy has been either ineffective or not tolerated along with:

- LDL-C > 500 mg/dl (Homozygotes)
- LDL-C ≥ 300 mg/dl (Heterozygotes) or
- LDL-C ≥ 200 mg/dl with documented CHD (Heterozygotes)



NIKKISO is well-known for providing extracorporeal technologies and products which meet the demands of the customers, patients, society and the modern times. Nikkiso is recognized as precision machinery company in the field of blood purification and hemodialysis. Beside our huge expertise in the development and production medical equipment, our R&D team has developed a new Cytapheresis Adsorber (Immunopure®) for the treatment of Ulcerative Colitis patients. For the easy use of this Cytapheresis Adsorber a blood pump has been developed.


Based in Hanover/Germany NIKKISO Europe GmbH is responsible for the distribution of the NIKKISO products in the EMEA region.

Synageva



Synageva is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company's pipeline programs consist of protein therapeutics for rare diseases with unmet medical need at various stages of development including the lead program, Kanuma™ (sebelipase alfa) for lysosomal acid lipase deficiency (LAL D), SBC-103 for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome), and SBC-105 for generalized arterial calcification of infancy (GACI) and other rare calcification diseases.

Scientific Program



WEDNESDAY, MAY 13, 2015

- 17:30-21:30** **Opening Key Note Address**
Chairperson: QFB Clotilde Estrada Carsolio ; Dr. Patrick Moriarty
Grand Cancun 4, 5A
-
- 17:30** **Global Challenges in Blood Donation**
Paul Strengers, Sanquin Blood Supply Foundation, The Netherlands
- 18:15** **Recognition to a Life in Transfusion Medicine**
- 18:45** **Opening Ceremony**
- 19:00** **100 years of Plasmapheresis**
Siami Ghodrat
Vanderbilt School of Medicine, USA
- 19:30** **Get Together Reception**

THURSDAY, MAY 14, 2015

- 08:30-09:15** **Plenary Session: 1**
Chairperson: Dr. Wolfgang Ramlow, *Germany* Grand Cancun 4, 5A
-
- 08:30** **Apheresis Technologies: Procedures and Equipment for Selective Target Removal**
Uwe H. Wallstab, *Engineering Office for Medical Technology, Germany*
-
- 09:15-10:00** **Plenary Session: 2**
Chairperson: Dr. Ángel Guerra Márquez Grand Cancun 4, 5A
-
- 09:15** **Use of Blood Components Based on the Recommendations of the Holland Blood Transfusion Conference**
Dr. Paul Strengers
-
- 10:00-10:30** **Plenary Session: 3**
Chairperson: Dra Fany Rosenfeld Mann Grand Cancun 4, 5A
-
- 10:00** **Microquimerismo Fetal Y Materno**
Ángel Guerra Márquez, *Mexico*
-
- 10:30-11:00** *Tea/Coffee Break and Exhibition Viewing* **Exhibition Foyer**
-
- 11:00-13:00** **Breakaway Session: Inflammatory Markers and Apheresis,**
Chairpersons: Dr. Patrick Moriarty, *USA*; Dr. Beate R. Jaeger, *Germany*
Gran Cancun 5
-
- 11:00** **Current Status and Future Perspectives of Lp(A) Apheresis**
Beate R. Jaeger, *Germany*
- 11:30** **Galectin-3 Removal and Apheresis**
Isaac Eliaz, *Econugenics, USA*
- 12:00** **Dynamics of Coronary Atherosclerosis in Post-CABG Patients Receiving Lipoprotein Apheresis**
Adzhiev Renad, *Russia*
- 12:30** **H.E.L.P.-Apheresis in Hypertensive Disorders of Pregnancy**
C. Contini^{1,4}; B. König¹; F. Markfeld-Erol²; M. Kunze²; S. Zschiedrich³;
H. Prömpeler²; G. Pütz¹; K. Winkler¹
¹*Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Freiburg*
²*Department of Obstetrics and Gynaecology, University Hospital Freiburg*
³*Renal Division, Department of Medicine, University Hospital Freiburg*
⁴*Hermann Staudinger Graduate School, University Freiburg*
-

THURSDAY, MAY 14, 2015 (CONT.)

11:00-13:00 Breakaway Session: Technology
Chairpersons: Dr. Paul Malchesky, *USA* ; Dr. Joerg Vienken, *Germany*
Cozumel 5

11:00 Membrane Technologies for Plasma Separation and Therapeutic Plasma Filtration
Paul Malchesky, International Center for Artificial Organs and Transplantation, USA

11:30 Basic Principles of Adsorption in Life Sciences
Joerg Vienken, Nephro-Solutions AG, Germany

12:00 Photopheresis – Current Status And Perspectives In Immunologically Driven Conditions
Volker Witt, St. Anna Kinderspital, Austria

12:30 Regulatory Process for Medical Devices in Europe: Current Status and Upcoming Revised Regulations
Uwe H. Wallstab¹, Jens Grothues²
¹Engineering Office Medical Technology U.WALLSTAB, Germany
²RegDev Ltd, UK

13:00-14:00 Lunch Break

14:00-15:30 Breakaway Session: Nephrology
Chairpersons: Dr. Wladimir Szpirt, *Denmark* ; Dr. Andre Kaplan, *USA*
Gran Cancun 5

14:00 Plasma Exchange in ANCA+ Vasculitis with Renal Involvement
Wladimir Szpirt, Rigshospitalet, Denmark

14:30 Plasma Exchange for Alveolar Hemorrhage in Vasculitis
Alina Casian, Guy's and St Thomas' NHS Foundation Trust, UK

14:00 Apheresis for Renal Disease: Current Status
Andre Kaplan, University of Connecticut Health Center, USA

THURSDAY, MAY 14, 2015 (CONT.)

14:00-15:00 Breakaway Session: Apheresis in Critical Care,
Chairperson: Dr. Jan Kielstein, *Germany*; Dr. Steffen Mitzner, *Germany*
Cozumel 5

14:00 Extracorporeal Therapy in Liver Disease, Current Strategies and Future Directions
Jody Olson, *University of Kansas Medical Center, USA*

14:30 What To Be Learned From Two Decades Of MARS Treatment In Liver Failure Patients?
Steffen Mitzner, *Biomedical Research Center Rostock, Germany*

15:00 Membrane vs. Centrifuge Based Therapeutic Plasma Exchange – A Randomized Prospective Crossover Study
Jan Kielstein, *Medical School Hannover, Germany*

15:30-16:00 Tea/Coffee Break and Exhibition Viewing *Exhibition Foyer*

16:00-17:30 Breakaway Session: Abstracts
Chairperson: Dr Siami Ghodrat, *USA*; Dr. Alina Casian, *UK*
Gran Cancun 5

16:00 Apheresis for Pediatric DCM
Takeshi Moriguchi, Kenichi Matsuda, Norikazu Harii,
Junko Goto, Masahiko Yanagisawa, Daiki Harada,
Sugawara Hisanori, Minako Hoshiai, Keiichi Koizumi
University of Yamanashi School of Medicine, Japan

16:15 To Assess the Incremental Cost Effectiveness of Treating Guillain Barre Syndrome Patient with Intravenous Immunoglobulin as Compared to Therapeutic Plasma Exchange
Ratti Ram Sharma, Ashish Maheshwari, Manish Modi,
Navneet Sharma, Shankar Prinja, Rekha Hans,
Neelam Marwaha, Rekha Hans, Neelam Marwaha
Postgraduate Institute of Medical Education and Research, India

16:30 A Novel Vascular Access Route for Granulocyte Monocyte Apheresis – Puncture of Accompanying Veins of Brachial Artery under Ultrasonographic Guidance
Norio Hanafusa, Toshihiro Torato, Daisuke Katagiri, Tomoko Usui,
Akihiko Matsumoto, Eisei Noiri, Masaomi Nangaku
The University of Tokyo Hospital, Japan

THURSDAY, MAY 14, 2015 (CONT.)

- 16:45** **Plasmapheresis of Pegylated Liposomal Doxorubicin: A New Approach to Reduce Toxicity during Chemotherapy (CARL-Trial)**
Stefan Zschiedrich¹, Jürgen Eckes¹, Oliver Schmah², Beate Rautenberg¹, Annette Hasenburg¹, Karl Winkler¹, Gerhard Pütz¹
¹University Medical Center Freiburg, Germany
²Caritas Klinikum Saarbrücken, Germany
- 17:00** **The Use of Vortex Port for Red Cell Exchange in Sickle Cell Disease Patient: Pilot Study**
Lydia Alexander, Imperial College Healthcare NHS Trust, UK
- 17:15** **The Immature Fraction of Platelets in Donor's Peripheral Blood Plateletapheresis**
Valery Pogorelov^{1,2}, Victoria Ufimceva¹, Lyudmila Ivanova¹, Beksoltam Urtaev², Igor Buchtijrov¹
¹Research Institute of Occupational Health the Russian Academy of Medical Sciences, Russia
²Moscow State University of Medicine and Dentistry, Russia
-
- 16:00-17:30** **Breakaway Session: Transplantation**
Chairperson: Dr. Jan Kielstein, Germany; Dr. Georg Boehmig, Austria
Cozumel 5
-
- 16:00** **The Role Apheresis Treatment before and after Kidney Transplantation**
Georg Boehmig, Medical University of Vienna, Austria
- 16:30** **Prolonging Survival after Orthotopic Heart Transplantation by Means of HELP Apheresis**
Beate Jaeger, Germany
- 17:00** **Intra-operative Therapeutic Plasma Exchange during Heart Transplant Surgery**
Ramakrishna Reddy, Sandy Bruning
Midwest Region, USA

FRIDAY, MAY 15, 2015

- 08:30-09:15** **Plenary Session 4:**
Chairperson: Dr. Wladimir Szpirt, *Denmark* Grand Cancun 4, 5A
-
- 08:30** **ICE – A Novel Extracorporeal System for Treatment of Septic Patients Utilizing Immobilized Granulocytes**
Steffen Mitzner, Biomedical Research Center Rostock, Germany
-
- 09:15-10:00** **Plenary Session 5:**
Chairperson: Dr Volker Witt, *Austria* Grand Cancun 4, 5A
-
- 09:15** **The Role of Apheresis in the Treatment of Ebola Virus Disease**
Anne Winkler, Emory Special Coagulation Laboratory, USA
-
- 10:00-10:45** **Plenary Session 6:**
Chairperson: Dra. Adolfin Bergés García Grand Cancun 4, 5A
-
- 10:00** **Síndrome Hiperhemolítico. Etiopatogenia Y Manejo Terapéutico**
Graciela León de González
-
- 10:45-11:30** *Tea/Coffee Break and Exhibition Viewing* *Exhibition Foyer*
-
- 11:30-13:00** **Breakaway Session: Immune Apheresis**
Chairperson: Dr. Jeffrey Winters, *USA*; Dr. Siami Ghodrat, *USA*
Grand Cancun 5
-
- 11:30** **Apheresis in the Treatment of Idiopathic Dilated Cardiomyopathy**
Jeffrey Winters, Mayo Clinic, USA
- 12:00** **Agonistic Autoantibodies to Adrenoceptors, Pathophysiological Role and Therapy**
Rudolf Kunze, Germany
- 12:30** **Double Column Immunoabsorption – An Effective Therapeutic Option in Immune Mediated Diseases**
Bernd Hohenstein
Extracorporeal Treatment and Lipoprotein Apheresis Center, Germany

FRIDAY, MAY 15, 2015 (CONT.)

11:30-13:00 Breakaway Session: Dyslipidemias
Chairperson: Dr. Beate R. Jaeger, *Germany*; Dr. Hans-Ulrich Kloer, *Germany*
Cozumel 5

11:30 KISS – A Cardiometabolic Risk Assessment Tool to Identify Dyslipidemic High-Risk Cardiovascular Patients in Daily Routine
Wolfgang Ramlow, *Apheresis Center Rostock, Germany*

12:00 Cross-Over Study Comparing the Liposorber Whole Blood and Plasma Lipid Apheresis System for Optimizing the Individual Therapy of Patients with Cardiovascular Disease and Severe Dyslipidemia
Grit Waitz, *BioArtProducts GmbH, Germany*

12:30 Severe Hypertriglyceridemia – An Indication for Apheresis Treatment
Hans-Ulrich Kloer, *Germany*

13:00-14:00 Lunch Break

14:00-15:30 Breakaway Session: Immune Apheresis
Chairperson: Dr. Bernd Hohenstein, *Germany*; Dr. Nico Melzer, *Germany*
Gran Cancun 5

14:00 Immunoabsorption In Neurological Diseases – An Effective Treatment Tool
Nico Melzer, *Germany*

14:30 A Possible Role for Immunoabsorption Treatment in Alzheimer's Diseases
Rudolf Kunze, *Germany*

15:00 Immunopure Cytapheresis: In Vitro Evaluations and First Clinical Results
Grit Waitz¹, Matthias Schneider², Heinrich Prophet², Wolfgang Ramlow²
¹*BioArtProducts GmbH, Germany*
²*Apheresis Center Rostock, Germany*

FRIDAY, MAY 15, 2015 (CONT.)

14:00-15:30 Breakaway Session: Dyslipidemia Continued
Chairperson: Dr. Hans-Ulrich Kloer, *Germany*; Dr. Patrick Moriarty, *USA*
Cozumel 5

14:00 Lysosomal Acid Lipase Deficiency – An Unrecognized Cause of Dyslipidemia
James Underberg, *Bellevue Hospital Lipid Clinic, USA*

14:20 Rheological Improvement In Lipid Apheresis – More than a Pleiotropic Effect?
Patrick Moriarty, *University of Kansas Medical Center, USA*

14:50 Treatment of PAD with Apheresis
Hisashi Makino, *National Cardiovascular Center, Japan*

15:30-16:00 Tea/Coffee Break and Exhibition Viewing *Exhibition Foyer*

16:00-18:00 Breakaway Session: PCSK9
Chairperson: Dr Patrick Moriarty, *USA*; Dr Bernd Hohenstein, *Germany*
Gran Cancun 5

16:00 Overview of PCSK9 and the Effect of Lipoprotein Apheresis on PCSK9 Levels
Bernd Hohenstein, *Extrakorporeal Treatment and Lipoprotein Apheresis Center, Germany*

16:30 PCSK9 Inhibitors for Patients with Statin Intolerance (Alternative Trial)
Patrick Moriarty, *University of Kansas Medical Center, USA*

17:00 FH Patients Receiving Lipoprotein Apheresis (Escape Trial)
Patrick Moriarty, *University of Kansas Medical Center, USA*

16:00-18:00 Breakaway Session: Sepsis
Chairperson: Yoshihiro Endo, *Japan*; Dr. Steffen Mitzner, *Germany*
Cozumel 5

16:00 Membrane vs. Centrifuge Based Therapeutic Plasma Exchange – A Randomized Prospective Crossover Study
Jan Kielstein, *Medical School Hannover, Germany*

16:30 The Efficacy of Direct Hemoperfusion with Polymyxin B Immobilized Fiber Column in Patients with Severe Sepsis and Septic Shock
Yoshihiro Endo¹, Tomoharu Shimizu¹, Tohru Tani²
¹*Shiga University of Medical Science, Japan*
²*Biomedical Innovation Center, Japan*

FRIDAY, MAY 15, 2015 (CONT.)

- 17:00 **Uncovering Complement-Mediated Thrombotic Microangiopathy in the Setting of Sepsis, Colitis, and Progressive Renal Failure**
Jan Hofmann¹, Dobri D. Kiproff²
¹*Apheresis Care Group, USA*
²*California Pacific Medical Center, USA*
- 17:30 **Analysis of Relationship between Central Venous Pressure and Hemodynamic Effect of Polymyxin-B Direct Hemoperfusion for Septic Shock Patients**
Hiroyuki Yamada, Tatsuo Tsukamoto, Motoko Yanagita
Graduate School of Medicine, Kyoto University, Japan

SATURDAY, MAY 16, 2015

- 08:30-09:15** **Plenary Session 7**
Chairman: Dr. Wolfgang Ramlow, *Germany* Grand Cancun 4, 5A
-
- 08:30** **Antisense Therapy Directed to Lp(A) For Lp(A)-Eligible Apheresis Patients**
Sotirios Tsimikas, *ISIS Pharmaceuticals, USA*
-
- 09:15-10:00** **Plenary Session 8**
Chairperson: Dr. Rudolf Kunze, *Germany* Grand Cancun 4, 5A
-
- 09:15** **Removal of C-reactive protein through Adsorption Techniques for Therapy of Myocardial Infarct and Stroke**
Ahmed Sherif², Ralf Schindler¹, Birgit Vogt², Rudolf Kunze³,
¹*Charité University Medicine Berlin, Germany*
²*Pentracor GmbH, Germany*
³*MDC Berlin, Germany*
-
- 10:00-10:45** **Plenary Session 9**
Chairperson: Dra. Malva H. Mejía Arregui Grand Cancun 4, 5A
-
- 10:00** **Utilidad de Biomarcadores Para Predecir Rechazo en Trasplante Renal y Estrategias de Desensibilización**
EBC. Julio César Martínez Álvarez
-
- 10:45-11:30** *Tea/ Coffee Break and Exhibition Viewing* *Exhibition Foyer*
-
- 11:30-13:00** **Breakaway Session: Regulatory Issues / Guidelines / Registers**
Chairperson: Dr. Beate R. Jaeger, *Germany*; Dr. Joerg Vienken, *Germany*
Gran Cancun 5
-
- 11:30** **Clinical Registers as Useful Tools to Improve the Data Base for Apheresis Treatments**
Christian Peter^{1,2}, Thomas Zimmermann¹, Wolfgang Ramlow^{1,3}
¹*BioArtProducts, Germany*
²*Fraunhofer Institute for Cell Therapy and Immunology, Germany*
³*Apherese Center, Germany*
-
- 12:00** **The German Lipid Apheresis Guidelines – A Good Basis for International Harmonization**
Wolfgang Ramlow, *Apheresis Center Rostock, Germany*
-
- 12:30** **An International Dyslipidemic Register - Ready To Go**
Christian Peter¹, Thomas Zimmermann¹, Wolfgang Ramlow^{1,2}
¹*BioArtProducts, Germany*
²*Apherese Center, Germany*
-

SATURDAY, MAY 16, 2015

11:30-13:00	Breakaway Session: Other Indications Chairperson: Dr. Robert Weinstein, USA; Dr. Dobri Kirpov, USA Cozumel 5
11:30	Unusual Indications for Therapeutic Leukapheresis in Hematological Malignancies <i>Robert Weinstein, University of Massachusetts Medical School, USA</i>
12:00	Heterochronic Intermittent Plasma Exchange for the Prevention of Cellular Senescence <i>Dobri Kirpov, USA</i>
12:30	Challenges for Apheresis Professionals in the Age of Emerging Cellular Therapies <i>Regina Rohe, USA</i>
13:30-14:30	Congress Closing Grand Cancun 4, 5A
14:30-15:30	ISFA General Assembly Grand Cancun 4, 5A

E POSTERS

1. **Effects of Single-pass Albumin Dialysis (SPAD) in Patients with Acute on Chronic Liver Failure (AoCLF) after Cardiac Surgery Intervention**
Assem Nogaibayeva¹, Bolat Bekishev¹, Fatikh Kacheganov¹, Timur Kapyshev¹, Assel Medressova¹
¹*National Research Cardiac Surgery Centre, Kazakhstan*
2. **TTP-like Syndrome Associated with Infectious Diseases: Pathogenesis and its Implication on Potential Treatment with Therapeutic Plasma Exchange (TPE)**
Jae Chang
University of California Irvine School of Medicine, USA
3. **Efficacy of the MICA Antibody for Transplant Patients**
Jin A Mo
National Evidence-based Health Care Collaborating Agency, South Korea
4. **Plasma Levels of Coronary Risk Biomarkers in Chronic Kidney Disease Patients under Maintenance Hemodialysis Treatment**
Koichiro Homma¹, Yasuhiko Homma², Joe Yoshizawa¹, Shingo Hori¹
¹*Keio University, Japan*
²*Tokai University, Japan*
5. **Agglutination due to Cold Antibodies during Plasmapheresis in a Healthy Donor**
Niubel Diaz Padilla, Fernando Gonzalez García, Arlinke Bokhorst
Sanquin Blood Supply, The Netherlands
6. **Effectiveness of the ST2 Test: Systematic Reviews**
Soyoung Kim
National Evidence-based Collaborating Agency, South Korea
7. **Side Effects during Protein A Immunoabsorption**
Rafael Ponikvar, Laura Poljancic, Jakob Gubensek, Andreja Marn Pernat, Vladimir Premru, Bojan Knap, Miha Benedik, Ana Zupunski Cede, Jadranka Buturovic Ponikvar
University Medical Center Ljubljana, Slovenia
8. **Citrate Anticoagulation Instead of Heparin in Primary Plasmapheresis Circuit of Protein a Immunoabsorption**
Rafael Ponikvar¹, Jakob Gubenšek^{1,2}, Andreja Marn Pernat¹, Bojan Knap¹, Vladimir Premru¹, Jadranka Buturovič Ponikvar^{1,2}
¹*University Medical Center Ljubljana, Slovenia*
²*University of Ljubljana, Slovenia*

E POSTERS (CONT.)

9. **Plasma Exchange Plus Continuous Hemofiltration and Hemoperfusion
for the Patients with Acute Toadstool Poisoning and MODS**

Xin Lin, Ying Xie, Jing Yuang, Yan Zha

The People's Hospital of Guizhou Province, China